<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438463</url>
  </required_header>
  <id_info>
    <org_study_id>PM/0037</org_study_id>
    <nct_id>NCT01438463</nct_id>
  </id_info>
  <brief_title>PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis</brief_title>
  <official_title>A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL® Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HAL Allergy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HAL Allergy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to characterize the dose-response relationship of
      PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms
      of clinical efficacy and safety.

      For this purpose 5 groups of 50 patients, suffering from rhinitis or rhinoconjunctivitis due
      to House Dust Mite Allergy will be treated during 1 year. Before start, after 6 months of
      treatment and at the end of the study patients will be subjected to a nasal provocation test.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity to House Dust Mite (HDM) allergen assessed by a Nasal Provocation Test</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity to HDM allergen assessed by a Nasal Provocation Test</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Adjusted daily Symptom Score (AAdSS)</measure>
    <time_frame>last 2 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Nasal Inspiratory Flow (PNIF)</measure>
    <time_frame>at each visit during 1 year treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific serum IgE, IgG, and IgG4 immunoglobulin concentrations to house dust mite</measure>
    <time_frame>6 and 12 months treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and systemic reactions after injection as a measure of Safety and Tolerability</measure>
    <time_frame>24 hours after each injection during 1 year treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PURETHAL Mites, 6,667 AU/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PURETHAL Mites, 20,000 AU/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PURETHAL Mites, 50,000 AU/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PURETHAL Mites, 100,000 AU/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PURETHAL Mites 6,667 AU/ml</intervention_name>
    <description>Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.</description>
    <arm_group_label>PURETHAL Mites, 6,667 AU/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PURETHAL Mites 20,000 AU/ml</intervention_name>
    <description>Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.</description>
    <arm_group_label>PURETHAL Mites, 20,000 AU/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PURETHAL Mites 50,000 AU/ml</intervention_name>
    <description>Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.</description>
    <arm_group_label>PURETHAL Mites, 50,000 AU/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PURETHAL Mites 100,000 AU/ml</intervention_name>
    <description>Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.</description>
    <arm_group_label>PURETHAL Mites, 100,000 AU/ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Patients (male or female) must be ≥ 18 and ≤ 60 years at screening

          -  Patients with allergic rhinitis or rhinoconjunctivitis for at least 1 year; allergic
             symptoms related to HDM, with or without concomitant clinically stable controlled mild
             to moderate asthma (according to GINA classification)

          -  Patients with a history of concomitant asthma should have a FEV1 &gt; 70% at inclusion.
             Patients without a history of asthma should have a FEV1 &gt; 70% or a PEF &gt; 80%.

          -  Positive SPT to HDM D. pter and/or D. far

          -  Serum specific IgE-test (ssIgE) level for HDM D. pter or D. far at screening

          -  Positive nasal provocation test for HDM extract at screening

        Exclusion Criteria:

          -  Current clinically relevant symptoms of seasonal rhinitis/rhinoconjunctivitis caused
             by other allergen(s) than HDM (with a demonstrated positive SPT for this allergen) at
             the time of inclusion

          -  Patients sensitized to animals should not be included if they are symptomatic upon
             exposure and regularly exposed to animals

          -  Completed allergen-specific immunotherapy (SCIT or SLIT) with HDM within the last 5
             years

          -  Completed unsuccessful allergen-specific immunotherapy (SCIT or SLIT) within the past
             5 years

          -  Allergen-specific immunotherapy (SCIT or SLIT) with other allergens than HDM during
             the study period

          -  Any vaccination one week before start of therapy and during the up-dosing phase

          -  Any anti-IgE therapy within the last 6 months prior to inclusion and during study

          -  Severe immune disorders (including auto-immune diseases) and/or diseases requiring
             immunosuppressive drugs

          -  Active malignancies or any malignant disease in the past 5 years

          -  A chronic or acute disease that in the opinion of the investigator might place the
             patient at an additional risk, including but not limited to the following:
             cardiovascular insufficiency, any severe or unstable lung diseases, endocrine
             disorders, clinically significant renal or hepatic diseases, or haematological
             disorders

          -  Moderate to severe nasal obstructive diseases such as polyps, septal deviations etc.

          -  Clinically significant chronic sinusitis or ocular infection

          -  Diseases with a contra-indication for the use of adrenaline (e.g. hyperthyroidism,
             glaucoma)

          -  Use of systemic corticosteroids within 4 weeks of screening

          -  Treatment with systemic or local b-blockers

          -  Participation in a clinical study with a new investigational drug within the last 3
             months or a biological within the last 6 months prior to the study or during the study

          -  Pregnancy, lactation or inadequate contraceptive measures (contraceptive measures
             considered as adequate include appropriate use of oral contraception, i.m.
             contraception or a contraceptive device)

          -  Alcohol, drug, or medication abuse within the past year and during study

          -  Any abnormal laboratory parameter at screening that in the opinion of the investigator
             is considered clinically relevant

          -  Lack of co-operation or compliance

          -  Severe psychiatric, psychological, or neurological disorders

          -  Patients who are employees of the department, 1st grade relatives, or partners of the
             investigator

          -  Expected changes in HDM exposure during the study (avoidance measures, move, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Bachert, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Gent, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ.-Klinik für Dermatologie und Venerologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Hals -, Nasen - und Ohrenheilkunde</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven campus Sint Rafaël</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO-Praxis Dr. Hippke</name>
      <address>
        <city>Berlin</city>
        <zip>D-13057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>D-53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO-Praxis</name>
      <address>
        <city>Chemnitz</city>
        <zip>D-09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Pneumologie und Allergologie Dr. Hans-Christian Blum</name>
      <address>
        <city>Dortmund</city>
        <zip>D-44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO-Praxis Dr. U. Thieme</name>
      <address>
        <city>Duisburg</city>
        <zip>D-47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum</name>
      <address>
        <city>Düren</city>
        <zip>D-52351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO Gemeinschaftspraxis</name>
      <address>
        <city>Göttingen</city>
        <zip>D-37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologische Praxis Hannover Nordstadt</name>
      <address>
        <city>Hannover</city>
        <zip>D-30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO Gemeinschaftspraxis</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO-Praxis</name>
      <address>
        <city>Jülich</city>
        <zip>D-52428</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>POIS Leipzig GbR</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRS Clinical Research Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRS Clinical Research Services Möchengladbach GmbH</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>D-41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis HNO/Allergologie</name>
      <address>
        <city>München</city>
        <zip>D-80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>D-80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologie Odeonsplatz</name>
      <address>
        <city>München</city>
        <zip>D-80539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO-Praxis</name>
      <address>
        <city>Pirna</city>
        <zip>D-01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft Reiber &amp; Partner</name>
      <address>
        <city>Schorndorf</city>
        <zip>D-73614</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70374</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70499</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Rhinologie und Allergologie</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65183</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EB FlevoResearch</name>
      <address>
        <city>Almere</city>
        <zip>NL-1311 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergologie Praktijk Arnhem (APA)</name>
      <address>
        <city>Arnhem</city>
        <zip>NL-6824 BJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer (Amstelwijck)</name>
      <address>
        <city>Dordrecht</city>
        <zip>NL-3317 NM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS Onderzoekskliniek Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>NL-9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabethziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>NL-5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trios i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-seasonal allergy</keyword>
  <keyword>house dust mite</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>dose response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

